Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Mastocytosis, and Stem Cell Conditioning Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KIT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | KIT ECD-Fc Fusion Protein Human/Mouse/Cyno orthologs. Sequence Verified. High Purity (>95%). Endotoxin <1EU/μg. HEK293 Expressed (Native Glycosylation). |
View KIT Products |
| Antigen (Mutants) | KIT Mutant Proteins (D816V, V560G, Δ550-557, V654A) Recombinant activation loop, juxtamembrane, and kinase domain mutations for resistance screening. |
View KIT Products |
| Gene Delivery | KIT Lentivirus Particles / ORF Clone Full-length wild-type ORF with reporter markers (GFP/Puro) for stable cell line construction (Ba/F3, CHO). High-titer premade particles. |
View KIT Products |
| Benchmark Ab | Anti-KIT Reference Antibodies (Clone YB5.B8; Sequence of Barzolvolimab / Briquilimab) Recombinant chimeric positive controls for binding, internalization, and functional assays. |
View KIT Products |
| Validator | KIT siRNA Set (3 unique targets) Validated knockdown sequences for specificity confirmation in cellular assays. |
View KIT Products |
| Related Target | PDGFRA Type III RTK homolog; co-mutated in GIST. Crucial for selectivity profiling and combination therapy. |
View PDGFRA Products |
| Related Target | FLT3 Type III RTK homolog; AML pathway overlap; essential for counter-screening. |
View FLT3 Products |
| Related Target | SCF (KIT Ligand) Natural ligand for competitive binding assays and receptor activation studies. |
View SCF Products |
| Related Target | CD47 Synergistic macrophage checkpoint target for non-genotoxic conditioning regimens. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutation Profiling (D816V, V560G, V654A, Exon 11/17) | Comprehensive KIT Mutant Panel (mass-spec verified, endotoxin controlled) for selectivity and resistance screening. |
| Selectivity over PDGFRA/FLT3 (Type III RTK Family) | Homolog Panel (KIT/PDGFRA/FLT3/CSF1R) with >95% purity; Sequence-verified ECDs for cross-reactivity ELISA/SPR. |
| Cross-species Cyno/Mouse Efficacy & Tox Evaluation | Human/Mouse/Cyno KIT ortholog proteins with native species-specific glycosylation (HEK293 expressed). |
| ADC Internalization & ADCC/ADCP Assessment | High-purity KIT ECD-Fc with native conformation; suitable for FACS internalization and effector function assays. |
| False Positive Elimination in Cellular Assays | Validated KIT siRNA set for target-specificity verification. |
| Lack of Reliable Positive Controls | Clinical Benchmark Antibodies (YB5.B8, Barzolvolimab biosimilar, Briquilimab biosimilar) included for direct affinity/functional comparison. |
Live KIT (CD117) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for KIT-driven malignancies is transitioning from first-generation multi-kinase inhibitors to highly selective mutant-specific inhibitors, antibody-drug conjugates (ADCs), and monoclonal antibodies for non-oncology indications. While imatinib revolutionized GIST treatment, acquired resistance mutations—particularly in the activation loop (D816V) and juxtamembrane domain—have necessitated next-generation small molecules such as avapritinib and ripretinib. Concurrently, first-generation TKI therapies are reaching maturity, driving a wave of R&D into non-oncology indications: non-genotoxic stem cell conditioning (replacing toxic chemotherapy prior to bone marrow transplants) and chronic immunological disorders like severe mastocytosis and chronic spontaneous urticaria. Key trends include:
- Mutation-specific inhibition: Compounds capable of distinguishing between primary and secondary resistance mutations (e.g., D816V vs. V560G).
- Non-genotoxic conditioning: Monoclonal antibodies like Briquilimab (Jasper Therapeutics) are pioneering targeted stem cell depletion for safer HSCT and gene therapy.
- Immunology expansion: Barzolvolimab (Celldex Therapeutics) targets mast cell-driven diseases (chronic urticaria, prurigo nodularis).
- ADC development: Leveraging KIT internalization for targeted payload delivery in GIST, AML, and melanoma.
- Combination strategies: KIT/PDGFRA dual targeting in GIST; KIT/FLT3 axis in AML; Anti-KIT + Anti-CD47 for enhanced macrophage-mediated clearance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Type I/II TKI) | Novartis, Deciphera, Blueprint Medicines | GIST (1st-3rd line), Advanced Systemic Mastocytosis | Mutant vs WT Selectivity (Need D816V, V560G, Exon 11/17 mutant proteins) |
| Allosteric Inhibitor | Novartis, Relay Therapeutics | Imatinib-resistant mutations | Conformational state binding (Need full-length lentivirus cell assays) |
| Monoclonal Antibody (Conditioning) | Jasper Therapeutics (Briquilimab) | Stem Cell Transplant, SCID, AML | ADCC/ADCP assays (Need HEK293-expressed ECD with native glycans) |
| Monoclonal Antibody (Immunology) | Celldex Therapeutics (Barzolvolimab) | Chronic Urticaria, Prurigo Nodularis | Receptor blocking assays (Need pure SCF ligand and KIT ECD) |
| ADC (Antibody-Drug Conjugate) | Daiichi Sankyo (DS-6157), Celldex, Early-stage Biotech | GIST, AML, Melanoma | Internalization assay (Need stable cell lines via TarMart Lentivirus) |
| Bispecific | Preclinical (Academic/Institutional) | Immunotherapy combinations | Homodimer/Heterodimer validation (Need cross-reactive species orthologs) |